Table of Contents Table of Contents
Previous Page  309 / 812 Next Page
Information
Show Menu
Previous Page 309 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S305

Methods

Retrospective analysis of clinical files of patients admit-

ted to our hospital unit with FEP diagnosis from January/2012

to April/2015. Clinician-rated dimensions of psychosis symptom

severity scales (DSM-5) were applied.

Results

Annual incidence of FEP was 11,3/100,000. From a total

of 755 patients, 57 (7,5%) corresponded to FEP; 38 (66,7%) were

diagnosed with SSP, 11 (19,3%) affective psychosis, 3 (5,2%) toxic

psychosis and 5 (8,8%) organic psychosis. Most were female

(61,4%), with a mean age of 49 years. The majority were unem-

ployed (66,7%), lived with family (57,9%), and presented with

moderate-severe delusions (80,1%), but without hallucinations

(57,8%), disorganized speech (59,6%) or negative symptoms (85,9%).

Affective FEP patients were older (61 vs 45 years), presented with

less severe psychotic symptoms (7,2 vs 8,3 points), but with higher

hospital admission (26,1 vs 21,1 days).

Conclusions

Regardless the growing interest concerning FEP, its

conceptualization and characterization remains controversial. Our

results differ from pre-existing literature data, especially concern-

ing gender and age. By including all the possible etiologies of FEP,

we aimed to obtain a more realistic characterization of this entity

in a real-world setting.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.656

EW539

Neutrophin signalling in first-episode

psychosis: relationship with

treatment response 1 year after the

illness onset

M. Martinez-cengotitabengoa

1 ,

, K. Macdowell

2

, S. Alberich

3

,

M. Parellada

4

, P. Saiz

5

, R. Rodriguez

6

, E. Berrocoso

7

,

M. Bernardo

8

, A. Gonzalez-pinto

9

, J.C. Leza

2

1

CIBERSAM-University Hospital of Alava- National Distance

Education University UNED, Psychiatry, Vitoria, Spain

2

CIBERSAM- Universidad Complutense de Madrid, Pharmacology,

Madrid, Spain

3

CIBERSAM- University Hospital of Alava, Psychiatry, Vitoria, Spain

4

CIBERSAM- Hospital General Universitario Gregorio Mara˜non-

Universidad Complutense de Madrid, Psychiatry, Madrid, Spain

5

CIBERSAM- Universidad de Oviedo, Psychiatry, Oviedo, Spain

6

CIBERSAM- Insituto de Investigacion 12 de Octubre, Psychiatry,

Madrid, Spain

7

CIBERSAM- Universidad de Cadiz, Pharmacology, Cadiz, Spain

8

CIBERSAM- Hospital Clinic y Universidad de Barcelona, Psychiatry,

Barcelona, Spain

9

CIBERSAM- University Hospital of Alava- University of the Basque

Country EHU-UPV, Psychiatry- Neurosciences, Vitoria, Spain

Corresponding author.

Introduction

Pro/antiinflammatory imbalance has been found

in first-episode psychotic (FEP) patients, even 12 months later.

Current research is every time more focused in the need to

find biomarkers to understand the underlying pathophysiological

mechanisms of this severe illness.

Objectives

To assess peripherical levels of neurotrophins and

their receptors and their correlation with inflammation, clinical

symptomatology and response to antipsychotic treatment, over the

time.

Methodology

Ninety-four FEP patients and 80 matched healthy

controls were included. Blood samples were taken at baseline to

measure BDNF and NGF and their receptor levels (TrkB-full, TrkB-

truncated and TrkA) and pro/antiinflammatory parameters (NFkB,

COX-2, iNOS, PPARgamma, 15d-PG12). Patients were followed-up

during 12 months.

Results

BDNF TrkB-full receptor and NFG TrkA receptor levels

increased during the follow-up whereas BDNF TrkB-truncated

form receptor decreased. After adjusting for confounding vari-

ables, baseline levels of proinflamatory variables were significantly

related to TrkB-full/TrkB-truncated ratio (FL/T), suggesting that

a higher proinflammatory status is related to a higher FL/T ratio

expression. Furthermore, baseline FL/T ratio could have a predic-

tor role of patient’s functionality 1 year after the illness onset,

depending on whether patient is treated or not with antipsychotic

drugs.

Conclusion

Inflammatory processes, neurotrophic pathways and

functional status of FEP patients seem to be relatedwhich is of great

traslational relevance. Specific, the expression of the 2 isoforms

of BDNF receptor should be taken into account before starting an

antipsychotic drug treatment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.657

EW540

Antipsychotic Medication Adherence

Scale (AMAS): Development and

preliminary psychometric properties

M.J. Martins

1 , 2 ,

, A.T. Pereira

2

, C.B. Carvalho

1 , 3

, P. Castilho

4

,

A.C. Lopes

5

, A. Oliveira

2

, C. Roque

2

, D. Mota

2

, F. Tróia

5

,

M. Bajouco

2

, N. Madeira

2

, O. Matos

5

, P. Santos

5

, R. Leite

5

,

S. Morais

2

, T. Santos

5

, T. Santos

5

, V. Nogueira

2

, V. Santos

2

,

A. Macedo

2

1

University of Coimbra, CINEICC, faculty of psychology and

educational sciences, Coimbra, Portugal

2

University of Coimbra, department of psychological medicine,

Coimbra, Portugal

3

University of Azores, education department, Azores, Portugal

4

University of Coimbra, faculty of psychology and educational

sciences, Coimbra, Portugal

5

Baixo Vouga hospital centre, department of psychiatry and mental

health, Aveiro, Portugal

Corresponding author.

Introduction

Although being highly consensual that antipsy-

chotic adherence is an important outcome predictor in psychosis,

existing reviews have found mean rates of adherence around

40–60%. Several aspects, such as patient-related, medication-

related, environmental-related variables have been described as

important predictors.

Aims

This study aim is to develop, administer and present pre-

liminary psychometric properties of a new scale for antipsychotic

medication adherence that includes different types of predictors

(clinical, psychosocial, and practical among others).

Methods

The “AMAS” was developed by a multidisciplinary team

and was based on recent research on factors influencing antipsy-

chotic adherence. The scale evolved from multiple drafts and

experts were contacted in order to improve the final version.

Over 50 patients with a diagnosis of a psychotic-spectrum dis-

order taking antipsychotic medication will be assessed with the

“AMAS” and the Medication Adherence Rating Scale. Additionally,

each patient’s psychiatrist will fill in a form with demographic

and clinical variables (such as type of symptoms, previous adher-

ence problems, current adherence, insight and other relevant

variables).

Results

This is an ongoing study and the sample is still being

collected (scheduled finish date: February/2016). Our statistical

analysis’ plan includes: reliability analysis (Chronbach’s alpha,

alpha if item deleted, inter item correlations and covariances and

item-total correlations); validity (convergent validity); factorial

analysis.

Conclusions

It is hypothesized that the “AMAS” will be a prac-

tical, reliable and valid unidimentional instrument with clinical

utility assessing adherence to antipsychotics. The “AMAS” can be

also useful in assessing intervention targets (e.g. psychoterapeuti-

cal, psychoeducational) to enhance adherence.